Information for the press


The full press programme and press releases (please scroll down) and videos will be
available on this page, and via EurekAlert ( http://www.eurekalert.org ) from Wednesday 12 June.


EULAR 2013 Press Registration

The online registration for journalists is now closed. Journalists can now register onsite only.
Please visit the press registration booth upon arrival to receive your press badge. You will need your
badge to access the press conferences and working rooms so please keep it with you at all times.


Video from the Press Conference Friday 14. June 2013

Part 1:


Part 2 | Part 3 | Part 4 | Part 5


Video from the Press Conference Thursday 13. June 2013

Part 1 | Part 2 | Part 3 | Part 4 | Part 5


Video from the Press Conference Wednesday 12. June 2013

Part 1 | Part 2 | Part 3 | Part 4 | Part 5


EULAR Press Area

The EULAR Press Office, journalist working rooms (including access to computers) and interview rooms are in Hall 10, Feria De Madrid.


The Press Office will be open at these times:

  • Wednesday 12 June 12:00 - 19:00
  • Thursday 13 June 08:00 - 19:00
  • Friday 14 June 08:00 - 19:00
  • Saturday 15 June 08:30 - 15:30

Refreshments are available throughout the congress for journalists


Official Press Activities

Daily press conferences will provide an overview of key data:

  • Wednesday 12 June:
    A data highlights press conference (five presentations)
    Timings: 13:30pm - 14:30pm
    Location: Room N115

  • Thursday 13 June:
    A data highlights press conference (five presentations)
    Timings: 09:00am - 09:45am
    Location: Room N115

  • Friday 14 June:
    A data highlights press conference (four presentations)
    Timings: 09:00am - 09:45am
    Location: Room N115


Interview Opportunities / Facilities

Experts will be available to comment on all musculoskeletal diseases; to schedule an interview or book a private interview room please contact the Press Office at eularpressoffice@uk.cohnwolfe.com

If you have any questions, or require any additional information before, please do not hesitate to contact a member of the EULAR Press Office team.


EULAR Press Office:

Francesca Russo
Onsite Tel: + 44 (0) 788 4114 754

eularpressoffice@uk.cohnwolfe.com

www.twitter.com/EULAR_Press

www.facebook.com/eular.org


Embargotime is CET
Press Releases for 13.06.14
Dr J Jarvis  Embargotime: 09:00 (CET)
Biomarkers predict long-term outcomes in juvenile idiopathic arthritis
Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) demonstrate the possibility of using biomarkers (developed from whole blood gene expression profiles) in children with juvenile idiopathic arthritis (JIA) to predict the status of their disease at 12 months. The long-term disease status at 12 months was accurately predicted only after treatment had been initiated, in newly diagnosed patients.
  View/Download this Press Release    


Dr A Avina-Zubieta  Embargotime: 09:00 (CET)
Sjögrens Syndrome significantly increases risk of myocardial infarction
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed a significantly increased risk of heart attack in patients with Sjögrens syndrome (SjS), particularly in the first year following diagnosis. There was also a trend towards an increased risk for stroke.
  View/Download this Press Release    


Dr A Van Der Zee-Neuen  Embargotime: 09:00 (CET)
New data highlight the higher health care cost burden of musculoskeletal conditions compared to other diseases
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) highlights the increased health care costs associated with musculoskeletal conditions compared to other diseases. Health care costs were almost 50% higher for people with a musculoskeletal condition compared to any other singly occurring condition.
  View/Download this Press Release    


Dr S Viatte  Embargotime: 09:00 (CET)
Genotyping can accurately predict disease outcomes in rheumatoid arthritis patients
New cohort studies presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) have shown the amino acid valine at position 11 of HLA-DRB1 gene to be the strongest independent genetic determinant of radiological damage in rheumatoid arthritis (RA). In addition, positions 71 and 74 were found to represent independent predictors, with the three positions together: 11, 71 and 74 strongly associated with disease outcomes.1
  View/Download this Press Release    


Press Releases for 12.06.14
Dr N Young  Embargotime: 09:00 (CET)
Regular exercise beneficial in suppressing inflammation in rheumatic disease
Research findings presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) suggest that exercise transiently suppresses local and systemic inflammation, reinforcing the beneficial effects of exercise and the need for this to be regular in order to achieve clinical efficacy in rheumatic disease.
  View/Download this Press Release    


Dr A Croft  Embargotime: 09:00 (CET)
Cranial ultrasound may replace temporal artery biopsy in diagnosis of giant cell arteritis
A new study presented for the first time today at the European League Against Rheumatism Annual Congress (EULAR 2014), shows that cranial ultrasound has a greater sensitivity than temporal artery biopsy, and a comparable specificity in the diagnosis of Giant Cell Arteritis (GCA).
  View/Download this Press Release    


Dr A Webster  Embargotime: 09:00 (CET)
Potential anti-TNF response biomarker identified
DNA methylation has been identified as a potential biomarker of response to etanercept and adalimumab in patients with rheumatoid arthritis (RA) according to preliminary results from one of the largest methylome-wide investigations of treatment response to anti-TNF therapies. These data, presented today at the European League Against Rheumatism Annual Congress (EULAR 2014), bring clinicians a step closer to being able to personalise a patients treatment pathway.
  View/Download this Press Release    


Dr N Schlesinger  Embargotime: 09:00 (CET)
All men with gout should be routinely screened for erectile dysfunction
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that erectile dysfunction (ED) is present in most men with gout and is frequently severe.
  View/Download this Press Release    


Press Releases for 11.06.14
Dr Z Touma  Embargotime: 13:30 (CET)
New guidance on how and when to stop immunosuppressants in lupus patients
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that, for the majority of lupus patients who are in remission, it is possible to successfully stop immunosuppressant therapy without triggering a flare of their disease. Within two years, it was possible to stop the immunosuppressant in about 70% of clinically stable patients. Half were successful within three years, and this proportion remained stable for up to five years.
  View/Download this Press Release    


  Embargotime: 13:30 (CET)
New patient empowerment and educational initiatives unveiled at EULAR 2014
Five different presentations at the European League Against Rheumatism Annual Congress (EULAR 2014) have introduced new patient empowerment and educational initiatives, which are predicted to bring significant benefits to the many thousands of patients worldwide who suffer from a rheumatic disease.
  View/Download this Press Release    


Dr W Park  Embargotime: 13:30 (CET)
Biosimilar CT-P13 matches infliximab in improving ankylosing spondylitis disease activity, disability and mobility
New data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that the newly-approved infliximab biosimilar CT-P13 achieves statistically similar improvements in disease activity, disability and mobility in patients with Ankylosing Spondylitis (AS) compared to its original reference product infliximab (INX).
  View/Download this Press Release    


Dr K Genant  Embargotime: 13:30 (CET)
Romosozumab significantly increases bone mineral density and bone content compared with teriparatide
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) shows that in postmenopausal women with low bone mass, romosozumab significantly increased bone mineral density and bone content in both the spine and hip compared to baseline, and also compared with the commonly prescribed anabolic agent teriparatide and placebo.
  View/Download this Press Release    


  Embargotime: 13:30 (CET)
One third of psoriatic arthritis patients are not receiving optimal dosing of adalimumab
Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNF±) inhibitor adalimumab necessary to achieve optimal clinical benefit. Further data revealed that, in the case of the TNF± inhibitor infliximab, nearly three-quarters of PsA patients were on doses lower than recommended in international guidelines.
  View/Download this Press Release    


  Embargotime: 13:30 (CET)
New data clarify relationship between diet and disease activity in different types of arthritis
Two new studies presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) have helped clarify the relationship between the dietary intake of monounsaturated fatty acids and cholesterol with disease activity in rheumatoid arthritis (RA) and osteoarthritis (OA) respectively.
  View/Download this Press Release    


Dr C Sparks  Embargotime: 13:30 (CET)
Higher disease activity scores in obese rheumatoid arthritis pts may lead to better outcomes due to more aggressive treatment
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that obese patients with rheumatoid arthritis (RA) have higher DAS (disease activity) scores than non-obese patients, irrespective of their disease stage. With clinical remission as the ultimate therapeutic goal in RA, several studies have demonstrated that treatment to target  a treatment approach guided by its impact on reducing DAS scores  is more effective in lowering disease activity and, ultimately, reaching remission than usual care. - Because obese patients have inflated DAS scores, treatment to target protocols may result in them being treated more aggressively than non-obese patients, which would explain the inverse relationship between body mass index (BMI) and outcomes in RA.
  View/Download this Press Release    


Dr P Le Goux  Embargotime: 13:30 (CET)
Tendon stimulation the key to repair in tennis elbow
New data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that ultrasound-guided injections of growth factors-containing platelet-rich plasma (PRP) are no more effective in treating recently developed epicondylitis than injections of saline.
  View/Download this Press Release    


Dr C Beyer  Embargotime: 13:30 (CET)
First biomarker to predict severe osteoarthritis
The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) identify a correlation between the presence of biomarkers in the blood, known as micro RNAs (miRNAs), and the development of severe osteoarthritis (OA) of the knee or hip joint. The findings suggest that miRNAs may be used as biomarkers to predict severe OA disease in individuals.
  View/Download this Press Release    


  Embargotime: 13:30 (CET)
EULAR driving research and innovation in rheumatic and musculoskeletal diseases (RMDs) in Europe
The European League Against Rheumatism (EULAR) has announced today at its Annual Congress major successes in driving the public agenda for addressing the escalating burden of RMDs in Europe. These advances include: - Recognition for Rheumatic and Musculoskeletal Diseases (RMDs) from major European Commission research initiative, Horizon 2020 -FOREUM, Foundation for Research in Rheumatology, grants research funding for four osteoarthritis projects in its first year.
  View/Download this Press Release    


Press Releases for 10.06.14
EULAR   Embargotime: 21:00 (CET)
EULAR media factsheet
Founded in 1947, the European League Against Rheumatism (EULAR) is the umbrella organisation which represents the patient, health professional and scientific societies for rheumatology across the European Union (EU).
  View/Download this Press Release    


EULAR   Embargotime: 21:00 (CET)
Rheumatic diseases in Europe Infographic
  View/Download this Press Release    


EULAR   Embargotime: 21:00 (CET)
Rheumatic diseases factsheet
Rheumatic diseases, also known as musculoskeletal diseases, are defined as disorders of the connective tissues. There are over 200 rheumatic diseases which typically affect the joints, tendons, ligaments, bones and muscles. Rheumatic diseases are treated as to whether they are non-inflammatory or inflammatory diseases. One quarter of Europe's population (>100 million people) suffer from a rheumatic disease.
  View/Download this Press Release    



RELATED INFORMATION


All you need to know

All you need to know about the onsite press activities including information regarding interview opportunities and facilities, the official press activities, conferences and press office information.

Download the PDF >>


Press & media code of practice

Activities of the press and media representatives are governed by the EULAR press and media rules and regulations.

Read EULAR press and media rules and regulations >>


 

EULAR Abstract Embargo Rules

The publication of abstracts is ruled by the abstract embargo rules.

Read rules >>